Zentalis Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the recipient of unusually large options trading on Wednesday. Stock investors purchased 2,113 call options on the company. This is an increase of 571% compared to the typical volume of 315 call options.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently modified their holdings of ZNTL. American Century Companies Inc. acquired a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter valued at about $95,000. Renaissance Technologies LLC raised its stake in Zentalis Pharmaceuticals by 152.6% during the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after purchasing an additional 399,745 shares during the period. Bank of Montreal Can acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at about $402,000. Squarepoint Ops LLC grew its stake in shares of Zentalis Pharmaceuticals by 543.8% in the 2nd quarter. Squarepoint Ops LLC now owns 148,755 shares of the company’s stock valued at $608,000 after buying an additional 125,649 shares during the period. Finally, Algert Global LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $78,000.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $1.89 on Thursday. The stock has a market capitalization of $134.68 million, a PE ratio of -0.76 and a beta of 1.86. The business has a 50 day simple moving average of $3.00 and a 200-day simple moving average of $3.30. Zentalis Pharmaceuticals has a 12 month low of $1.76 and a 12 month high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. On average, equities research analysts anticipate that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on ZNTL. Wedbush reaffirmed a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Guggenheim decreased their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. UBS Group dropped their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday. Finally, HC Wainwright decreased their price objective on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Zentalis Pharmaceuticals has a consensus rating of “Hold” and an average price target of $8.58.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.